前收市價 | 120.80 |
開市 | 121.40 |
買盤 | 118.60 x 100000 |
賣出價 | 119.00 x 150000 |
今日波幅 | 121.00 - 122.00 |
52 週波幅 | 91.10 - 124.60 |
成交量 | |
平均成交量 | 122 |
市值 | 無 |
Beta 值 (5 年,每月) | 無 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | 無 |
業績公佈日 | 2024年7月30日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 無 |
On Thursday, the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) unanimously voted to recommend Merck & Co Inc’s (NYSE:MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for adults 65 years of age and older. It is also commonly known as the pneumonia vaccine. Specifically, the ACIP voted to recommend a single dose of Capvaxive for: Adults 65 years and older who have not previously received a pneumococcal conjugate vaccine or wh
Merck's (MRK) vaccine, Capvaxive, gets unanimous recommendation by a CDC committee for adults aged 65 years and older for pneumococcal vaccination and those with certain other underlying conditions.
Merck stock tumbled under its 50-day moving average Thursday after the FDA rejected its Daiichi Sankyo-partnered cancer drug.